DK1470818T3 - Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS - Google Patents

Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS

Info

Publication number
DK1470818T3
DK1470818T3 DK03291024T DK03291024T DK1470818T3 DK 1470818 T3 DK1470818 T3 DK 1470818T3 DK 03291024 T DK03291024 T DK 03291024T DK 03291024 T DK03291024 T DK 03291024T DK 1470818 T3 DK1470818 T3 DK 1470818T3
Authority
DK
Denmark
Prior art keywords
hours
neuroprotective
pns
cns
phenothiazine derivatives
Prior art date
Application number
DK03291024T
Other languages
Danish (da)
English (en)
Inventor
Aline Appert-Colin
Noelle Callizot
Original Assignee
Neuro3D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuro3D filed Critical Neuro3D
Application granted granted Critical
Publication of DK1470818T3 publication Critical patent/DK1470818T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
DK03291024T 2003-04-25 2003-04-25 Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS DK1470818T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03291024A EP1470818B1 (fr) 2003-04-25 2003-04-25 Utilisation de dérivés de phénothiazine pipérazine pour la préparation d'un médicament ayant des effets neuroprotecteurs et/ou neurotrophiques sur le SNC et/ou SNP

Publications (1)

Publication Number Publication Date
DK1470818T3 true DK1470818T3 (da) 2006-11-20

Family

ID=32946961

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03291024T DK1470818T3 (da) 2003-04-25 2003-04-25 Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS

Country Status (9)

Country Link
US (1) US20060276460A1 (fr)
EP (1) EP1470818B1 (fr)
AT (1) ATE333881T1 (fr)
DE (1) DE60307049T2 (fr)
DK (1) DK1470818T3 (fr)
ES (1) ES2272911T3 (fr)
HK (1) HK1066741A1 (fr)
PT (1) PT1470818E (fr)
WO (1) WO2004096231A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2911143A1 (fr) * 2007-01-05 2008-07-11 Servier Lab Utilisation de composes neuroprotecteurs pour l'obtention de medicaments destines au traitement de maladies neurodegeneratives.
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
DE102010062810B4 (de) * 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
EP2758403B1 (fr) * 2011-09-21 2016-04-27 Inception Orion, Inc. Composés tricycliques utiles comme agents neurogènes et neuroprotecteurs
WO2015135947A1 (fr) * 2014-03-10 2015-09-17 Universite D'aix-Marseille Dérivés de phénothiazine pipérazine pour le traitement de la spasticité

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3058979A (en) * 1957-05-13 1962-10-16 Smith Kline French Lab New perfluoroalkylphenothiazine derivatives
US3194733A (en) * 1961-04-26 1965-07-13 Olin Mathicson Chemical Corp Phenothiazine compositions and method of treating mental disorders
US3320245A (en) * 1964-08-21 1967-05-16 American Home Prod Derivatives of phenothiazine-10-glyoxylic acids and intermediates in the preparationthereof
US3320249A (en) * 1965-07-09 1967-05-16 Olin Mathieson Adamantyl derivatives of phenothiazines
CA2115792C (fr) * 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
EP0778773A1 (fr) * 1994-08-08 1997-06-18 Albert Einstein College Of Medicine Of Yeshiva University Procedes permettant de traiter et/ou de prevenir la maladie d'alzheimer a l'aide de phenothiazines et/ou de thioxanthenes
US6514686B2 (en) * 1997-04-28 2003-02-04 The University Of British Columbia Method and composition for modulating amyloidosis
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
WO1999007356A1 (fr) * 1997-08-11 1999-02-18 University Of South Florida Research Foundation, Inc. Antagonistes de la nicotine permettant de traiter des troubles neuropsychiatriques
FR2784678B1 (fr) * 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
CA2350597A1 (fr) * 1998-12-02 2000-06-08 Barbara Ann Foster Procedes et compositions pour retablir la stabilite de conformation d'une proteine de la famille p53
WO2001078709A2 (fr) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Traitement des maladies neurodegeneratives
CA2310205A1 (fr) * 2000-05-29 2001-11-29 Dalhousie University Inconnu
ATE510837T1 (de) * 2000-09-13 2011-06-15 Vertex Pharma Caspase inhibitoren und deren verwendung
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
AU2003222197A1 (en) * 2002-01-16 2003-09-02 The Regents Of The University Of California Inhibition of rna function
FR2835254B1 (fr) * 2002-01-25 2006-04-07 Sod Conseils Rech Applic Derives de thiazoles dans le traitement de maladies neurologiques

Also Published As

Publication number Publication date
DE60307049D1 (de) 2006-09-07
US20060276460A1 (en) 2006-12-07
ATE333881T1 (de) 2006-08-15
HK1066741A1 (en) 2005-04-01
WO2004096231A2 (fr) 2004-11-11
EP1470818B1 (fr) 2006-07-26
DE60307049T2 (de) 2007-02-08
WO2004096231A3 (fr) 2005-03-24
PT1470818E (pt) 2006-11-30
ES2272911T3 (es) 2007-05-01
EP1470818A1 (fr) 2004-10-27

Similar Documents

Publication Publication Date Title
NO991951L (no) Tienopyrimidiner med fosfodiesterase V-inhiberende virkning
Shirazi et al. 1, 25-Dihydroxyvitamin D3 enhances neural stem cell proliferation and oligodendrocyte differentiation
Calkins et al. Assessment of newly synthesized mitochondrial DNA using BrdU labeling in primary neurons from Alzheimer's disease mice: Implications for impaired mitochondrial biogenesis and synaptic damage
NO20081367L (no) Fenyl- og pyridyl-1,2,4-oksadiazolonderivater med fenylgruppe, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytika
NO955219L (no) Nye kjemiske forbindelser med PDE-IV-inhiberende aktivitet
DE60324449D1 (de) Inhibitoren der phosphodiesterase der zyklischen n, und deren verwendung in therapie
DE502004006219D1 (de) Neue 8-(piperazin-1-yl)- und 8-( 1,4 diazepan-1-yl)-xanthine, deren herstellung und deren verwendung als arzneimittel
NO20054726L (no) 2, 4-di(fenylamino)pyrimidiner anvendelige ved behandling av neoplastiske sykdommer, inflammasjons- og immunsystemforstyrrelser
DE3686927D1 (de) Neovaskularisierungsinhibitoren und deren herstellung.
WO2005046570A3 (fr) Materiaux de cellule souche humaine et procedes associes
UY29077A1 (es) Amidas sustituidas de ácido tienopirrolcarboxílico, amidas del ácido pirrolotiazolcarboxílico y análogos relacionados como inhibidores de la caseína cinasa ie(epsilon)
Pei et al. Sevoflurane suppresses microglial M2 polarization
CY1110417T1 (el) Παραγωγα τρυπταμινης και αναλογες ενωσεις και φαρμακευτικες φαρμακοτεχνικες μορφες που περιεχουν αυτα
DK1470818T3 (da) Anvendelse af Piperazin-phenothiazin-derivater til fremstilling af et medikament med neurobeskyttende og/eller neurotrofiske effekter på CNS og/eller PNS
WO2006044842A3 (fr) Procedes et matieres de cellules embryonnaires
AU2003293746A1 (en) Crystalline cefdinir salts
Swayne et al. Ion channels in postnatal neurogenesis: potential targets for brain repair
DK1513800T3 (da) Benzoylureido-kanelsyrederivater, fremgangsmåde til deres anvendelse
DE60230774D1 (de) Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern
NO20072972L (no) Terapeutiske pyrazolo[3,4-B]pyridiner og indazoler
TW200508179A (en) Purification of dimethylacetamide (DMAc)
NO933960L (no) Interleukinreseptor-maalsoekende molekyler for behandling av inflam matorisk artritis
DE59904875D1 (de) Substituierte phenyl-alkenoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikamente oder diagnostika sowie sie enthaltende medikamente
HUP0100611A2 (hu) Triazin vegyületek, és ilyeneket tartalmazó gyógyszerkészítmények a központi idegrendszer elváltozásainak kezelésére
ES2125879T3 (es) Triazaespirodecanona-metilcromanos para el tratamiento de enfermedades del sistema nervioso central.